Search

everythinglearnresearchcommunity

for

Search:↓

Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

A cancer patient died from a severe skin reaction after taking the drug cetuximab.

A woman developed a severe skin reaction called toxic epidermal necrolysis after taking the antibiotic cephalexin.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.

Cell therapy is advancing with stem cell transplants and genetically modified cells improving treatment for diseases like cancer and autoimmune disorders.

Cyclosporin is effective in treating dog skin diseases and has fewer side effects compared to other treatments.

Lysocellin helps stop cell damage from etoposide and may prevent hair loss.

Intravenous cyclophosphamide effectively treated steroid-resistant lupus cystitis and peritonitis.

A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.

Enhancing immune response can improve cancer treatment effectiveness.

The document concludes that treatment for cutaneous T-cell lymphoma should be customized to each patient's disease stage, balancing benefits and side effects, with no cure but many patients living long lives.

Pimecrolimus reduces the effectiveness of stem cell therapy for atopic dermatitis.

Cyclosporine cleared a woman's resistant skin condition quickly and kept it away for over a year.

VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.

Cetuximab often causes skin problems, but they can be managed without stopping treatment.

Mycophenolate mofetil is safer and more effective than cyclophosphamide for treating lupus nephritis.

TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.

Cetuximab often causes skin rashes, and managing these is important for cancer treatment.

A 65-year-old man developed a serious skin cancer linked to a drug he was taking for a fungal infection after a bone marrow transplant.

Baicalin may help treat severe drug-induced skin reactions.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

Infliximab was effective in treating a scalp condition that did not respond to other treatments.

The cancer drugs bortezomib and lenalidomide cause skin side effects in many patients.

CEP135 may predict cancer outcomes, and targeting PLK1 could help treat certain sarcomas.

Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.

Lenalidomide effectively and safely treats skin symptoms in pediatric lupus, reducing the need for prednisone.